Tags

Type your tag names separated by a space and hit enter

Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice.
Clin Exp Immunol. 2008 Nov; 154(2):264-9.CE

Abstract

In humans and animal models of atherosclerosis, antibodies against oxidized LDL have been associated with atherosclerotic lesion development. It has been suggested that IgM anti-oxLDL antibodies are anti-atherogenic, whereas IgG anti-oxLDL antibodies are pro-atherogenic. In this study, we examined the relation between IgM and IgG antibody levels and atherosclerosis severity in APOE(-/-)CD40L(-/-) mice, which are deficient for IgG and develop moderate advanced atherosclerosis, and compared results with mice developing severe (APOE(-/-)) or no atherosclerosis (C57Bl/6). Mice were followed in time for anti-oxLDL antibodies while on high-fat diet or normal chow. Anti-oxLDL antibody levels were determined by ELISA. Results revealed that 24-week-old APOE(-/-)CD40L(-/-) mice had enhanced IgM anti-oxLDL antibody levels when compared with wild-type mice, but similar levels to those of APOE(-/-) mice. As expected, IgG anti-oxLDL antibody levels were almost absent in APOE(-/-)CD40L(-/-) mice. The transition from early to advanced lesions in APOE(-/-) mice was reflected by elevated IgM anti-oxLDL antibody levels. IgM anti-oxLDL levels did not further increase during progression to more advanced lesions. No relation was found between IgG anti-oxLDL levels and atherosclerosis severity. In conclusion, the severity of advanced atherosclerosis in mice is not reflected by IgM and/or IgG anti-oxLDL antibody levels. Furthermore, less advanced atherosclerotic lesion development in APOE(-/-)CD40L(-/-) mice does not seem to be the result of higher levels of protective IgM anti-oxLDL antibodies. Therefore, our study does not support the idea that the previously observed inconsistency in the relation between anti-oxLDL and atherosclerosis severity is due to differences in antibody isotypes.

Authors+Show Affiliations

Department of Internal Medicine, Section Clinical & Experimental Immunology, Maastricht University, Maastricht, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18778362

Citation

Smook, M L F., et al. "Anti-oxLDL Antibody Isotype Levels, as Potential Markers for Progressive Atherosclerosis in APOE and APOECD40L Mice." Clinical and Experimental Immunology, vol. 154, no. 2, 2008, pp. 264-9.
Smook ML, van Leeuwen M, Heeringa P, et al. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Clin Exp Immunol. 2008;154(2):264-9.
Smook, M. L., van Leeuwen, M., Heeringa, P., Damoiseaux, J. G., Theunissen, R., Daemen, M. J., Lutgens, E., & Tervaert, J. W. (2008). Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Clinical and Experimental Immunology, 154(2), 264-9. https://doi.org/10.1111/j.1365-2249.2008.03746.x
Smook ML, et al. Anti-oxLDL Antibody Isotype Levels, as Potential Markers for Progressive Atherosclerosis in APOE and APOECD40L Mice. Clin Exp Immunol. 2008;154(2):264-9. PubMed PMID: 18778362.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. AU - Smook,M L F, AU - van Leeuwen,M, AU - Heeringa,P, AU - Damoiseaux,J G M C, AU - Theunissen,R, AU - Daemen,M J A P, AU - Lutgens,E, AU - Tervaert,J W Cohen, Y1 - 2008/09/05/ PY - 2008/9/10/pubmed PY - 2008/12/17/medline PY - 2008/9/10/entrez SP - 264 EP - 9 JF - Clinical and experimental immunology JO - Clin. Exp. Immunol. VL - 154 IS - 2 N2 - In humans and animal models of atherosclerosis, antibodies against oxidized LDL have been associated with atherosclerotic lesion development. It has been suggested that IgM anti-oxLDL antibodies are anti-atherogenic, whereas IgG anti-oxLDL antibodies are pro-atherogenic. In this study, we examined the relation between IgM and IgG antibody levels and atherosclerosis severity in APOE(-/-)CD40L(-/-) mice, which are deficient for IgG and develop moderate advanced atherosclerosis, and compared results with mice developing severe (APOE(-/-)) or no atherosclerosis (C57Bl/6). Mice were followed in time for anti-oxLDL antibodies while on high-fat diet or normal chow. Anti-oxLDL antibody levels were determined by ELISA. Results revealed that 24-week-old APOE(-/-)CD40L(-/-) mice had enhanced IgM anti-oxLDL antibody levels when compared with wild-type mice, but similar levels to those of APOE(-/-) mice. As expected, IgG anti-oxLDL antibody levels were almost absent in APOE(-/-)CD40L(-/-) mice. The transition from early to advanced lesions in APOE(-/-) mice was reflected by elevated IgM anti-oxLDL antibody levels. IgM anti-oxLDL levels did not further increase during progression to more advanced lesions. No relation was found between IgG anti-oxLDL levels and atherosclerosis severity. In conclusion, the severity of advanced atherosclerosis in mice is not reflected by IgM and/or IgG anti-oxLDL antibody levels. Furthermore, less advanced atherosclerotic lesion development in APOE(-/-)CD40L(-/-) mice does not seem to be the result of higher levels of protective IgM anti-oxLDL antibodies. Therefore, our study does not support the idea that the previously observed inconsistency in the relation between anti-oxLDL and atherosclerosis severity is due to differences in antibody isotypes. SN - 1365-2249 UR - https://www.unboundmedicine.com/medline/citation/18778362/Anti_oxLDL_antibody_isotype_levels_as_potential_markers_for_progressive_atherosclerosis_in_APOE_and_APOECD40L_mice_ L2 - https://doi.org/10.1111/j.1365-2249.2008.03746.x DB - PRIME DP - Unbound Medicine ER -